This study is looking at a medicine called itepekimab to see if it is safe and works well for people with COPD, a lung condition that makes it hard to breathe. The study will last up to 72 weeks, which is a little over a year. You will take the medicine for up to 52 weeks and then be checked on for another 20 weeks after stopping. There will be 7 visits to the study site and 5 phone calls to check on you.

To join, you must have finished a previous study with itepekimab. You cannot join if you had certain health problems like cancer or serious infections during the last study.

• **Length of Study**: Up to 72 weeks
• **Number of Visits**: 7 on-site and 5 by phone
• **Eligibility**: Completed a previous itepekimab study